April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 USD | +0.16% | -4.98% | +21.51% |
April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+21.51% | 4.22B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.45% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |